WO1996006110A1 - Proteines composites se fixant a de l'adn et substances et procedes concernant ces proteines - Google Patents

Proteines composites se fixant a de l'adn et substances et procedes concernant ces proteines Download PDF

Info

Publication number
WO1996006110A1
WO1996006110A1 PCT/US1995/010557 US9510557W WO9606110A1 WO 1996006110 A1 WO1996006110 A1 WO 1996006110A1 US 9510557 W US9510557 W US 9510557W WO 9606110 A1 WO9606110 A1 WO 9606110A1
Authority
WO
WIPO (PCT)
Prior art keywords
dna
protein
binding
complex
cells
Prior art date
Application number
PCT/US1995/010557
Other languages
English (en)
Inventor
Inc. Ariad Pharmaceuticals
Original Assignee
Gilman, Michael, Z.
Natesan, Sridaran
Pollock, Roy, M.
Botfield, Martyn, C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilman, Michael, Z., Natesan, Sridaran, Pollock, Roy, M., Botfield, Martyn, C. filed Critical Gilman, Michael, Z.
Priority to AU33315/95A priority Critical patent/AU3331595A/en
Publication of WO1996006110A1 publication Critical patent/WO1996006110A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • This invention provides a method and materials for achieving high-level and controllable expression of such a target gene.
  • the invention makes use of novel composite proteins containing multiple or composite DNA-binding domains designed to recognize, preferably with high affinity and specificity, DNA sequences associated with the target gene. This affinity and specificity are achieved by combining independent heterologous DNA-binding domains, by either covalent or non-covalent means, into a composite DNA-binding protein that recognizes a corresponding DNA sequence, preferably with very high affinity.
  • the target gene can be activated to high levels of expression.
  • undesirable side-effects associated with the inadvertent activation of other genes is avoided.
  • This disclosure focuses on the use of composite DNA-binding proteins, in which the component DNA-binding domains are covalently or non- covalently joined together, to obtain high level constitutive or regulated expression of a target gene for use in gene therapy, production of biological materials, and biological research.
  • This invention involves novel DNA- binding proteins containing two or more heterologous DNA-binding domains which are linked together covalently or through an association mediated by a multimerizing agent (the terms “multimerize” and “dimerize” are used interchangably herein).
  • the invention further involves DNA sequences encoding such proteins, the recombinant DNA sequences to which the composite DNA-binding proteins bind (i.e., which are recognized by the composite DNA-binding proteins), constructs containing a target gene and a DNA sequence which is recognized by the composite DNA-binding proteins, and the use of these materials in gene therapy, production of biological materials, and biological research.
  • "Composite” as the term is used herein indicates that the protein contains component domains derived from at least two different proteins, domains from at least two non-adjacent portions of the same protein, or domains which are not found so linked in nature.
  • Such composite proteins and DNA sequences which encode them are recombinant in the sense that they contain at least two constituent portions which are not otherwise found directly linked (covalently) together in nature. Desirable properties of these proteins include high affinity for specific DNA sequences, low affinity for most other sequences in a complex genome (such as human), low dissociation rates from specific DNA sites, and novel DNA recognition specificities distinct from those of known natural DNA-binding proteins.
  • a basic principle of the design is the assembly of multiple DNA-binding domains into a single protein molecule or complex that recognizes a long and complex DNA sequence with high affinity through the combined interactions of the individual domains.
  • a further benefit of this design is the avidity derived from multiple independent protein-DNA interactions.
  • the composite DNA binding protein in certain embodiments is a single chimeric protein containing multiple and covalently-linked copies of one or more DNA-binding domains, while in other embodiments the composite DNA-binding protein comprises two (or more) "subunits", each of which is a chimeric protein in its own right containing at least one DNA-binding domain. In the latter case, the composite DNA-binding protein comprises two or more such subunits in a multimerizer-mediated association.
  • the system comprises: (1) a DNA construct encoding and directing the expression of a composite DNA-binding protein containing two or more heterologous component DNA-binding domains and one or more additional domains, as described below, or one or more DNA constructs encoding chimeric proteins, each containing one or more ligand- binding domains, DNA-binding domains and additional domains, which chimeras are capable of associating in the presence of a multimerizing agent, to form a composite DNA-binding protein (complex); (2) a DNA construct containing a target gene and one or more copies of a DNA sequence to which the composite DNA-binding protein is capable of binding, preferably with high affinity and /or specificity; and (3) optionally, one or more DNA constructs encoding and directing the expression of additional proteins capable of modulating the activity of the DNA-binding protein.
  • the composite DNA binding protein whether formed by covalent linking or ligand-mediated multimerization of component parts, bind to a corresponding DNA sequence selectively, i.e., bind to that DNA sequence observable despite the presence of numerous alternative candidate DNA sequences.
  • binding of the multimerized chimeras or composite DNA binding protein to the selected DNA sequence is at least two, more preferably three and even more preferably more than four orders of magnitude greater than binding to any one alternative DNA sequence, as measured by relative rates or levels of transcription of genes associated with the selected and any alternative DNA sequences.
  • the selected DNA sequence be recognized to a substantially greater degree by the multimerized chimeras than by the non-multimerized chimeras, or by a protein containing a composite DBD than by a protein containing only some of the individual components thereof.
  • the level of expression of a target gene is preferably two, more preferably three and even more preferably more than four orders of magnitude greater in the presence of the multimerizing ligand than in its absence, as determined by any measure of transcription or target gene expression, including those described below.
  • target gene expression is preferably two, more preferably three, and even more preferably more than four orders of magnitude greater in the presence of a composite transcription factor containing a composite DBD than in the presence of a protein containing only some of the components of the composite DBD.
  • Each covalently-linked or unitary composite DNA-binding protein consists of two or more protein domains capable of recognizing (i.e., binding to) specific sequences in DNA.
  • the individual component domains may be separated by linker amino acids that permit the simultaneous contact of each domain with the DNA target.
  • the combined action of the composite DNA-binding domain formed by the component DNA-binding modules results in the addition of the free energy decrement of each set of interactions. The effect is to achieve a DNA-protein interaction of very high affinity, preferably with dissociation constant below 10 " 9 M, more preferably below 10"10 M, even more preferably below 10"H M.
  • Suitable component DNA-binding domains have one or more, preferably more, of the following properties. They bind DNA as monomers, although dimers can be accommodated. They should have modest affinities for DNA, with dissociation constants in the range of 10"6 to 10"9 M. They should optimally belong to a class of DNA-binding domains whose structure and interaction with DNA are well understood and therefore amenable to manipulation. For gene therapy applications, they are preferably derived from human proteins.
  • the multimerizer-linked composite DBPs comprise two or more chimeric proteins, each comprising at least one binding site for a multimerizing ligand, at least one component DBD such as mentioned above and described in further detail herein, and one or more optional domains, as discussed below.
  • chimeric proteins containing ligand binding sites and capable of ligand-mediated multimerization see e.g., Spencer et al, 1993, Science, supra, and PCT/US94/01617.
  • DNA-binding domains with appropriate DNA binding properties may be selected from several different types of natural DNA-binding proteins.
  • One class is proteins that normally bind DNA only in conjunction with auxiliary DNA- binding proteins, usually in a cooperative fashion, where both proteins contact DNA and each protein contacts the other.
  • this class include the homeodomain proteins, many of which bind DNA with low affinity and poor specificity, but act with high levels of specificity in vivo due to interactions with partner DNA-binding proteins.
  • yeast alpha2 protein which binds DNA only in cooperation with another yeast protein Mcml.
  • Another example is the human homeodomain protein Phoxl, which interacts cooperatively with the human transcription factor, serum response factor (SRF).
  • SRF serum response factor
  • a second class is proteins in which the DNA-binding domain is comprised of multiple reiterated modules that cooperate to achieve high- affinity binding of DNA.
  • An example is the C2H2 class of zinc-finger proteins, which typically contain a tandem array of from two or three to dozens of zinc- finger modules. Each module contains an alpha-helix capable of contacting a three base-pair stretch of DNA. Typically, at least three zinc-fingers are required for high-affinity DNA binding. Therefore, one or two zinc-fingers constitute a low-affinity DNA-binding domain with suitable properties for use as a component in this invention.
  • proteins of the C2H2 class include TFIIIA, Zif268, Gli, and SRE-ZBP. (These and other proteins and DNA sequences referred to herein are well known in the art. Their sources and sequences are known.)
  • a third general class is proteins that themselves contain multiple independent DNA-binding domains. Often, any one of these domains is insufficient to mediate high-affinity DNA recognition, and cooperation with a covalently linked partner domain is required.
  • Examples include the POU class, such as Oct-1, Oct-2 and Pit-1, which contain both a homeodomain and a POU- specific domain; HNF1, which is organized similarly to the POU proteins; certain Pax proteins (examples: Pax-3, Pax-6), which contain both a homeodomain and a paired box/domain; and XXX, which contains a homeodomain and multiple zinc-fingers of the C2H2 class.
  • An additional strategy for obtaining component DNA-binding domains with properties suitable for this invention is to modify an existing DNA- binding domain to reduce its affinity for DNA into the appropriate range.
  • a homeodomain such as that derived from the human transcription factor Phoxl, may be modified by substitution of the glutamine residue at position 50 of the homeodomain. Substitutions at this position remove or change an important point of contact between the protein and one or two base pairs of the 6-bp DNA sequence recognized by the protein. Thus, such substitutions reduce the free energy of binding and the affinity of the interaction with this sequence and may or may not simultaneously increase the affinity for other sequences. Such a reduction in affinity is sufficient to effectively eliminate occupancy of the natural target site by this protein when produced at typical levels in mammalian cells.
  • domains that amenable to this type of manipulation include the paired box, the zinc-finger class represented by steroid hormone receptors, the myb domain, and the ets domain.
  • linker sequence for covalently linked composite DBDs.
  • the linker sequence separates adjacent DNA-binding domains. It should be selected or designed to permit the independent interaction of each domain with DNA without steric interference.
  • a linker may also be selected or designed so as to impose specific spacing and orientation on the DNA-binding domains.
  • the linker amino acids may be derived from endogenous flanking peptide sequence of the component domains or may comprise one or more heterologous amino acids. Linkers may be designed by modeling or by experimental trial.
  • Additional domains may be included in the various chimeric proteins of this invention.
  • the chimeric proteins will contain a cellular targeting sequence which provides for the protein to be translocated to the nucleus.
  • This nuclear localization sequence has a plurality of basic amino acids, referred to as a bipartite basic repeat (reviewed in Garcia-Bustos et al, Biochimica et Biophysica Acta (1991) 1071, 83-101). This sequence can appear in any portion of the molecule internal or proximal to the N- or C-terminus and results in the chimeric protein being inside the nucleus.
  • the chimeric proteins may include domains that facilitate their purification, e.g.
  • “histidine tags” or a glutathione- S-transferase domain may include “epitope tags” encoding peptides recognized by known monoclonal antibodies for the detection of proteins within cells or the capture of proteins by antibodies in vitro. They may also include one or more transcriptional activation domains, such as the well- characterized domain from the viral protein VP16 or novel activation domains of different designs. For instance, one may use one or multiple copies of transcriptional activating motifs from human proteins, including e.g.
  • Chimeric proteins which contain both a composite DNA-binding domain and a transcriptional actibating domain thus comprise composite transcription factors.
  • the chimeric proteins may include regulatory domains that place the function of the DNA-binding domain under the control of an external ligand; one example would be the ligand-binding domain of steroid receptors.
  • the chimeric proteins may also include a ligand-binding domain to provide for regulatable interaction of the protein with a second polypeptide chain.
  • the unitary composite DNA-binding protein may further contain a ligand-binding domain.
  • the presence of a ligand- binding domain permits association of the composite DBP, in the presence of a dimerizing ligand, with a second chimeric protein containing a transcriptional activation domain and another ligand-binding domain.
  • the transcriptional activation domain may be present on a chimeric protein which further contains one or more component DNA-binding domains, which is capable of dimerizing, in the presence of a dimerizing agent, with another chimeric protein of this invention bearing a ligand-binding domain and one or more additional component DNA-binding domains.
  • a composite DNA-binding protein complex is formed which further contains the transcriptional activation domain and any other optional domains.
  • Multimerizing ligands useful in practicing this invention are multivalent, i.e., capable of binding to, and thus multimerizing, two or more of the chimeric protein molecules.
  • the multimerizing ligand may bind to the chimeras containing such ligand-binding domains, in either order or simultaneously, preferably with a Kd value below about 10 ⁇ 6, more preferably below about 10"* 7 , even more preferably below about 10" ⁇ , and in some embodiments below about 10"9 M.
  • the ligand preferably is not a protein or polypeptide and has a molecular weight of less than about 5 kDa, preferably below 2 kDa.
  • the ligand-binding domains of the chimeric proteins so multimerized may be the same or different. See e.g. PCT/US93/01617, the full contents of which are hereby incorporated by reference.
  • Target DNA sequence The DNA sequences recognized by the composite DNA-binding domains present in these proteins or protein complexes can be determined experimentally, as described below, or the proteins can be manipulated to direct their specificity toward a desired sequence.
  • a desirable recognition sequence consists of at least twelve base pairs, preferably fifteen or even eighteen or more. These base pairs need not be fully contiguous; they may be interspersed with "spacer" base pairs that are not directly contacted by the protein but rather impose proper spacing between the subsites recognized by each module. These sequences should not impart expression to linked genes when introduced into cells in the absence of the engineered DNA-binding protein.
  • each component domain is independently capable of binding DNA with low affinity (dissociation constants in the range of 10 ⁇ 6 to 10 ⁇ 9 M)
  • the linker (L) is a stretch of amino acids of any length that permits a suitable orientation of the two DBDs on a single DNA molecule permitting binding to a target DNA with a dissociation constant below about 10" 9 M.
  • DBD component domain
  • L linker
  • HD is a homeodomain (61 amino acids, with additional flanking sequences as necessary to obtain proper folding and stability) and ZF is one or two C2H2 zinc fingers separated by a natural zinc-finger linker (the H/C link).
  • ZF is one or two C2H2 zinc fingers separated by a natural zinc-finger linker (the H/C link).
  • the boundaries of such domains are well characterized as is well known in the art.
  • these proteins can take the form of:
  • each chimeric protein contains only a subset or portion of one of the foregoing composite DBDs, together with other domains such as linker, ligand-binding, and other optional domains.
  • DNA-binding domains Individual component DNA- binding domains may be further modified by mutagenesis to decrease, increase, or change the recognition specificity of DNA binding. These modifications could be achieved by rational design of substitutions in positions known to contribute to DNA recognition (often based on homology to related proteins for which explicit structural data are available). For example, in the case of a homeodomain, substitutions can be made in amino acids in the N- terminal arm, first loop, second helix, and third helix known to contact DNA. In zinc fingers, substitutions can be made at selected positions in the DNA recognition helix. Alternatively, random methods, such as selection from a phage display library could be used to identify altered domains with increased affinity or altered specificity.
  • Additional domains may be appended to either the N- or C-termini of the DNA-binding domains in any order consistent with the proper functioning of the protein (as may be readily observed experimentally).
  • DNA sequences encoding individual DNA-binding sub-domains and linkers, if any, are joined such that they constitute a single open reading frame encoding a composite DBD that can be translated in cells or cell lysates into a single polypeptide harboring all domains.
  • This protein-encoding sequence is then placed into a conventional plasmid vector that directs the expression of the protein in the appropriate cell type.
  • plasmids that direct the expression of the protein in bacteria or in reticulocyte-lysate systems.
  • the protein-encoding sequence is introduced into an expression vector that directs expression in these cells.
  • DNA sequences encoding a DNA-binding domain is joined to DNA encoding one or more suitably engineered ligand- binding domains, and if desired, to DNA encoding a transcriptional activation domain or other optional domain(s).
  • DNA sequences are joined such that they constitute a single open reading frame that can be translated in cells into a single polypeptide harboring all component domains.
  • the order and arrangement of the domains within the polypeptide can vary. At least two such chimeras are required for the optimal embodiment of this method.
  • constructions encode polypeptides containing distinct DNA-binding domains, ligand-binding domains with distinct specificity for multimerizing moieties, and in some embodiments, transcriptional activation domains with different properties.
  • this invention includes chimeras of the following structure:
  • immunophilin represents 1, 2 or 3 immunophilin domains, such as the FKBP12 domain of Spencer et al, "txn activator” represents a VP16 domain and "DNA binding domain” represents a DNA binding domain of Phoxl or SRE-ZBP.
  • high-affinity binding sites for the protein or protein complex can be selected from a large pool of random DNA sequences by adaptation of published methods (Pollock, R. and Treisman, R., 1990, A sensitive method for the determination of protein-DNA binding specificities. Nucl. Acids Res. 18, 6197-6204). Bound sequences are cloned into a plasmid and their precise sequence and affinity for the proteins are determined. From this collection of sequences, individual sequences with desirable characteristics (i.e., maximal affinity for composite protein, minimal affinity for individual subdomains) are selected for use. Alternatively, the collection of sequences is used to derive a consensus sequence that carries the favored base pairs at each position. Such a consensus sequence is synthesized and tested (see below) to confirm that it has an appropriate level of affinity and specificity.
  • the DNA construct that enables the target gene to be regulated by DNA-binding proteins of this invention is a fragment, plasmid, or other nucleic acid vector carrying a synthetic transcription unit consisting of: (1) one copy or multiple copies of a DNA sequence recognized with high-affinity by the composite DNA-binding protein or protein complex; (2) a promoter sequence consisting minimally of a TATA box and initiator sequence but optionally including other transcription factor binding sites; (3) sequence encoding the desired product (protein or RNA), including sequences that promote the initiation and termination of translation, if appropriate; (4) an optional sequence consisting of a splice donor, splice acceptor, and intervening intron DNA; and (5) a sequence directing cleavage and polyadenylation of the resulting RNA transcript.
  • a synthetic transcription unit consisting of: (1) one copy or multiple copies of a DNA sequence recognized with high-affinity by the composite DNA-binding protein or protein complex; (2) a promoter sequence consisting minimally of a TATA box and initiator
  • a number of well-characterized assays are available for determining the binding affinity, usually expressed as dissociation constant, for DNA-binding proteins and their cognate DNA sequences. These assays usually require the preparation of purified protein and binding site (usually a synthetic oligonucleotide) of known concentration and specific activity. Examples include electrophoretic mobility-shift assays, DNasel protection or "footprinting", and filter-binding. These assays can also be used to get rough estimates of association and dissociation rate constants. These values may be determined with greater precision using a BIAcore instrument. In this assay, the synthetic oligonucleotide is bound to the assay "chip,” and purified DNA-binding protein is passed through the flow-cell.
  • Binding of the protein to the DNA immobilized on the chip is measured as an increase in refractive index. Once protein is bound at equilibrium, buffer without protein is passed over the chip, and the dissociation of the protein results in a return of the refractive index to baseline value. The rates of association and dissociation are calculated from these curves, and the affinity or dissociation constant is calculated from these rates. Binding rates and affinities for the high affinity composite site may be compared with the values obtained for subsites recognized by each subdomain of the protein. As noted above, the difference in these dissociation constants should be at least two orders of magnitude and preferably three or greater.
  • the above-mentioned plasmids are introduced together into tissue culture cells by any conventional transfection procedure, including for example calcium phosphate coprecipitation, electroporation, and lipofection. After an appropriate time period, usually 24- 48 hr, the cells are harvested and assayed for production of the reporter protein. In embodiments requiring dimerization of chimeric proteins for activation of transcription, the assay is conducted in the presence of the dimerizing agent. In an appropriately designed system, the reporter gene should exhibit little activity above background in the absence of any co-transfected plasmid for the composite transcription factor (or in the absence of dimerizing agent in embodiments under dimerizer control).
  • reporter gene expression should be elevated in a dose-dependent fashion by the inclusion of the plasmid encoding the composite transcription factor (or plasmids encoding the multimerizable chimeras, followed by multimerizing agent). This result indicates that there are few natural transcription factors in the recipient cell with the potential to recognize the tested binding site and activate transcription and that the engineered DNA-binding domain is capable of binding to this site inside living cells.
  • the transient transfection assay is not a stringent test in most cases, because the high concentrations of plasmid DNA in the transfected cells lead to unusually high concentrations of the DNA-binding protein and its recognition site, allowing functional recognition even with relative low affinity interactions.
  • a more stringent test of the system is a transfection that results in the integration of the introduced DNAs at near single-copy. Thus, both the protein concentration and the ratio of specific to non-specific DNA sites would be very low; only very high affinity interactions would be expected to be productive. This scenario is most readily achieved by stable transfection in which the plasmids are transfected together with another plasmid encoding an unrelated selectable marker (e.g., G418-resistance).
  • an unrelated selectable marker e.g., G418-resistance
  • Transfected cell clones selected for drug resistance typically contain copy numbers of the nonselected plasmids ranging from zero to a few dozen. A set of clones covering that range of copy numbers can be used to obtain a reasonably clear estimate of the efficiency of the system.
  • Virus stocks derived from such a construction will generally lead to single-copy transduction of the genes.
  • transgenic animals carrying similar DNAs to determine whether the protein is functional in an animal.
  • the recognition specificity of the protein can be changed. Substituting the amino acid at position 50 of a homeodomain, changes the recognition specificity for positions 5 and 6 in the 6 base-pair binding site. Similar mutations in the recognition helix of zinc fingers also change DNA recognition specificity. In the case of zinc fingers, phage display has been used effectively to select zinc fingers that recognize a given three base-pair sequence.
  • Constructs encoding the composite DNA-binding proteins, constructs encoding related chimeric proteins (e.g. in the case of regulatable expression systems) and constructs directing the expression of target genes, all as described herein, can be introduced into cells as one or more DNA molecules or constructs, in many cases in association with one or more markers to allow for selection of host cells which contain the construct(s).
  • the constructs can be , prepared in conventional ways, where the coding sequences and regulatory regions may be isolated, as appropriate, ligated, cloned in an appropriate cloning host, analyzed by restriction or sequencing, or other convenient means.
  • constructs including all or portions of a functional unit may be isolated, where one or more mutations may be introduced using "primer repair", ligation, in vitro mutagenesis, etc. as appropriate.
  • the construct(s) once completed and demonstrated to have the appropriate sequences may then be introduced into a host cell by any convenient means.
  • the constructs may be integrated and packaged into non- replicating, defective viral genomes like Adenovirus, Adeno-associated virus (AAV), or Herpes simplex virus (HSV) or others, including retroviral vectors, for infection or transduction into cells.
  • the constructs may include viral sequences for transfection, if desired.
  • the construct may be introduced by fusion, electroporation, biolistics, transfection, lipofection, or the like.
  • the host cells will in some cases be grown and expanded in culture before introduction of the construct(s), followed by the appropriate treatment for introduction of the construct(s) and integration of the construct(s).
  • the cells will then be expanded and screened by virtue of a marker present in the construct.
  • markers which may be used successfully include hprt, neomycin resistance, thymidine kinase, hygromycin resistance, etc.
  • one may have a target site for homologous recombination, where it is desired that a construct be integrated at a particular locus.
  • a recombinant target construct of this invention For homologous recombination, one may generally use either ⁇ or O-vectors. See, for example, Thomas and Capecchi, Cell (1987) 51, 503-512; Mansour, et al, Nature (1988) 336, 348-352; and Joyner, et al, Nature (1989) 338, 153-156.
  • the constructs may be introduced as a single DNA molecule encoding all of the genes, or different DNA molecules having one or more genes.
  • the constructs may be introduced simultaneously or consecutively, each with the same or different markers.
  • Vectors containing useful elements such as bacterial or yeast origins of replication, selectable and /or amplifiable markers, promoter/enhancer elements for expression in procaryotes or eucaryotes, etc. which may be used to prepare stocks of construct DNAs and for carrying out transfections are well known in the art, and many are commercially available.
  • Cells which have been modified ex vivo with the DNA constructs may be grown in culture under selective conditions and cells which are selected as having the desired construct(s) may then be expanded and further analyzed, using, for example, the polymerase chain reaction for determining the presence of the construct in the host cells.
  • modified host cells Once modified host cells have been identified, they may then be used as planned, e.g. grown in culture or introduced into a host organism. Depending upon the nature of the cells, the cells may be introduced into a host organism, e.g. a mammal, in a wide variety of ways.
  • Hematopoietic cells may be administered by injection into the vascular system, there being usually at least about 104 cells and generally not more than about 10l0, more usually not more than about 108 cells.
  • the number of cells which are employed will depend upon a number of circumstances, the purpose for the introduction, the lifetime of the cells, the protocol to be used, for example, the number of administrations, the ability of the cells to multiply, the stability of the therapeutic agent, the physiologic need for the therapeutic agent, and the like.
  • the number of cells would depend upon the size of the layer to be applied to the burn or other lesion.
  • the number of cells will be at least about 10 ⁇ and not more than about l ⁇ 8 and may be applied as a dispersion, generally being injected at or near the site of interest.
  • the cells will usually be in a physiologically-acceptable medium.
  • Cells engineered in accordance with this invention may also be encapsulated, e.g. using conventional materials and methods. See e.g. Uludag and Sefton, 1993, J Biomed. Mater. Res. 27(10):1213-24; Chang et al, 1993, Hum Gene Ther 4(4):433-40; Reddy et al, 1993, J Infect D ⁇ s 168(4):1082-3; Tai and Sun, 1993, FASEB J 7(ll):1061-9; Emerich et al, 1993, Exp Neurol 122(l):37-47; Sagen et al, 1993, J Neurosci 13(6):2415-23; Aebischer et al, 1994, Exp Neurol 126(2):151-8; Savelkoul et al, 1994, J Immunol Methods 170(2):185-96; Winn et al, 1994, PNAS USA 91(6):2324-8; Emerich et al, 1994, Prog Neuropsycho
  • the cells may then be introduced in encapsulated form into an animal host, preferably a mammal and more preferably a human subject in need thereof.
  • the encapsulating material is semipermeable, permitting release into the host of secreted proteins produced by the encapsulated cells.
  • the semipermeable encapsulation renders the encapsulated cells immunologically isolated from the host organism in which the encapsulated cells are introduced.
  • the cells to be encapsulated may express one or more chimeric proteins containing components domains derived from viral proteins or proteins from other species (and need not contain a composite DNA binding domain as described above).
  • the chimeras may contain elements derived from GAL4 and VP16.
  • the cells may be engineered as disclosed in International Patent Applications PCT/US94/01617 or PCT/US94/08008 or in US Patent Application Serial Nos. 08/292,595 and 08/292,596 (filed August 18, 1994), the full contents of which are incorporated herein by reference.
  • virus vectors have been developed, such as adenovirus, adeno-associated virus. and retroviruses, which allow for transfection and random integration of the virus into the host. See, for example, Debunks et al. (1984) Porch. Natl. Acad. Sci. USA 81, 7529-7533; Caned et al., (1989) Science 243,375-378; Hiebert et al. (1989) Proc. Natl. Acad. Sci.
  • the vector may be administered by injection, e.g. intravascularly or intramuscularly, inhalation, or other parenteral mode.
  • the manner of the modification will depend on the nature of the tissue, the efficiency of cellular modification required, the number of opportunities to modify the particular cells, the accessibility of the tissue to the DNA composition to be introduced, and the like.
  • an attenuated or modified retrovirus carrying a target transcriptional initiation region if desired, one can activate the virus using one of the subject transcription factor constructs, so that the virus may be produced and transfect adjacent cells.
  • the DNA introduction need not result in integration in every case. In some situations, transient maintenance of the DNA introduced may be sufficient. In this way, one could have a short term effect, where cells could be introduced into the host and then turned on after a predetermined time, for example, after the cells have been able to home to a particular site.
  • This invention is applicable to any situation that calls for expression of an exogenously-introduced gene embedded within a large genome.
  • the desired expression level could be preset very high or very low.
  • the system may be further engineered to achieve regulated or titratable expression. See e.g. PCT/US93/01617. In most cases, the inadvertent activation of unrelated cellular genes is undesirable.
  • one application of this invention to gene therapy is the delivery of a two-transcription-unit cassette (which may reside on one or two plasmid molecules, depending on the delivery vector) consisting of (1) a transcription unit encoding a protein composed of a composite DNA-binding domain constructed according to this invention and a strong transcription activation domain (e.g., derived from the VP16 protein) and (2) a transcription unit consisting of the therapeutic gene expressed under the control of a minimal promoter carrying one, and preferably several, binding sites for the composite DNA-binding domain.
  • Cointroduction of the two transcription units into a cell results in the production of the hybrid transcription factor which in turn activates the therapeutic gene to high level.
  • This strategy essentially incorporates an amplification step, because the promoter that would be used to produce the therapeutic gene product in conventional gene therapy is used instead to produce the activating transcription factor.
  • Each transcription factor has the potential to direct the production of multiple copies of the therapeutic protein.
  • This method may be employed to increase the efficacy of many gene therapy strategies by substantially elevating the expression of the therapeutic gene, allowing expression to reach therapeutically effective levels.
  • therapeutic genes that would benefit from this strategy are genes that encode secreted therapeutic proteins, such as cytokines (e.g., 1L-2, IL-4, IL-12), growth factors (e.g., VEGF), antibodies, and soluble receptors.
  • Other candidate therapeutic genes are disclosed in PCT/US93/01617.
  • This strategy may also be used to increase the efficacy of "intracellular immunization" agents, molecules like ribozymes, antisense RNA, and dominant-negative proteins, that act either stoichiometrically or by competition. Examples include agents that block infection by or production of HIV or hepatitis virus and agents that antagonize the production of oncogenic proteins in tumors.
  • a recombinant transcription factor which comprises a composite DNA-binding domain, a potent transcriptional activation domain, and a regulatory domain controllable by a small orally-available ligand.
  • a recombinant transcription factor which comprises a composite DNA-binding domain, a potent transcriptional activation domain, and a regulatory domain controllable by a small orally-available ligand.
  • a recombinant transcription factor which comprises a composite DNA-binding domain, a potent transcriptional activation domain, and a regulatory domain controllable by a small orally-available ligand.
  • ligand-binding domain of steroid receptors in particular the domain derived from the modified progesterone receptor described by Wang et al, 1994, Proc Natl Acad
  • the composite DNA binding domain of this invention is used in place of the GAL4 domain in the recombinant transcription factor and the target gene is linked to a DNA sequence recognized by the composite DNA binding domain.
  • a design permits the regulation of a target gene by known anti-progestins such as RU486
  • the transcription factors described here greatly enhance the efficacy of this regulatory domain because of the enhanced affinity of the DNA-binding domain, the absence of background activity that arises from ligand-independen dimerization directed by the GAL4 domain in published constructs, and the reduced potential for immunogenicity because human sequences are substituted for yeast.
  • the first chimeric protein comprises a composite DNA-binding domain as described herein and a receptor domain (e.g. FKBP) for which a ligand, preferably a high-affinity ligand, is available.
  • the second chimeric protein comprises an activation domain and a second receptor domain (which may be the same or different than on the prior chimeric protein).
  • the dimerizing reagent is capable of binding to the receptor (or "ligand binding") domains present on each of the chimeras and thus of dimerizing or oligomerizing the chimeras.
  • DNA molecules encoding and directing the expression of these chimeric proteins are introduced into the cells to be engineered. Also introduced into the cells is a target gene linked to a DNA sequence to which the composite DNA-binding domain is capable of binding. Contacting the engineered cells or their progeny with the oligomerizing reagen leads to regulated activity of the transcription factor and hence to expression of the target gene.
  • the design and use of similar components is disclosed in PCT /US93/ 01617. These may be adapted to the present invention by the use of composite DNA-binding domain, and DNA sequence encoding it, in place of the alternative DNA-binding domains as disclosed in the referenced patent document.
  • the dimerizing ligand may be administered to the patient as desired to activate transcription of the target gene.
  • various protocols may be employed.
  • the ligand may be administered parenterally or orally. The number of administrations will depend upon the factors described above.
  • the ligand may be taken orally as a pill, powder, or dispersion; bucally; sublingually; injected intravascularly, intraperitoneally, subcutaneously; by inhalation, or the like.
  • the ligand (and monomeric antagonist compound) may be formulated using conventional methods and materials well known in the art for the various routes of administration. The precise dose and particular method of administration will depend upon the above factors and be determined by the attending physician or human or animal healthcare provider. For the most part, the manner of administration will be determined empirically.
  • a monomeric compound which can compete with the dimerizing ligand may be administered.
  • an antagonist to the dimerizing agent can be administered in any convenient way, particularly intravascularly, if a rapid reversal is desired.
  • cells may be eliminated through apoptosis via signaling through Fas or TNF receptor as described elsewhere. See International Patent Applications PCT/US94/01617 and PCT/US94/08008.
  • the particular dosage of the ligand for any application may be determined in accordance with the procedures used for therapeutic dosage monitoring, where maintenance of a particular level of expression is desired over an extended period of times, for example, greater than about two weeks, or where there is repetitive therapy, with individual or repeated doses of ligand over short periods of time, with extended intervals, for example, two weeks or more.
  • a dose of the ligand within a predetermined range would be given and monitored for response, so as to obtain a time-expression level relationship, as well as observing therapeutic response. Depending on the levels observed during the time period and the therapeutic response, one could provide a larger or smaller dose the next time, following the response. This process would be iteratively repeated until one obtained a dosage within the therapeutic range.
  • the ligand is chronically administered, once the maintenance dosage of the ligand is determined, one could then do assays at extended intervals to be assured that the cellular system is providing the appropriate response and level of the expression product.
  • the system is subject to many variables, such as the cellular response to the ligand, the efficiency of expression and, as appropriate, the level of secretion, the activity of the expression product, the particular need of the patient, which may vary with time and circumstances, the rate of loss of the cellular activity as a result of loss of cells or expression activity of individual cells, and the like. Therefore, it is expected that for each individual patient, even if there were universal cells which could be administered to the population at large, each patient would be monitored for the proper dosage for the individual.
  • Protein expression may prevent cells from growing to high density, sharply reducing production levels. Therefore, the ability to tightly control protein expression, as described for regulated gene therapy, permits cells to be grown to high density in the absence of protein production. Only after an optimum cell density is reached, is expression of the gene activated and the protein product subsequently harvested.
  • a similar problem is encountered in the construction and use of "packaging lines" for the production of recombinant viruses for commercial (e.g., gene therapy) and experimental use.
  • These cell lines are engineered to produce viral proteins required for the assembly of infectious viral particles harboring defective recombinant genomes.
  • Viral vectors that are dependent on such packaging lines include retrovirus, adenovirus, and adeno-associated virus.
  • the titer of the virus stock obtained from a packaging line is directly related to the level of production of the viral rep and core proteins. But these proteins are highly toxic to the host cells. Therefore, it has proven difficult to generate high-titer recombinant viruses.
  • This invention provides a solution to this problem, by allowing the construction of packaging lines in which the rep and core genes are placed under the control of regulatable transcription factors of the design described here.
  • the packaging cell line can be grown to high density, infected with helper virus, and transfected with the recombinant viral genome. Then, expression of the viral proteins encoded by the packaging cells is induced by the addition of dimerizing agent to allow the production of virus at high titer.
  • Biological research This invention is applicable to a wide range of biological experiments in which precise control over a target gene is desired. These include: (1) expression of a protein or RNA of interest for biochemical purification; (2) regulated expression of a protein or RNA of interest in tissue culture cells for the purposes of evaluating its biological function; (3) regulated expression of a protein or RNA of interest in transgenic animals for the purposes of evaluating its biological function; (4) regulating the expression of another regulatory protein that acts on an endogenous gene for the purposes of evaluating the biological function of that gene.
  • Transgenic animal models and other applications in which the composite DNA-binding domains of this invention may be used include those disclosed in US Patent Application Serial Nos. 08/292,595 and 08/292,596 (filed August 18, 1994).
  • kits useful for the foregoing applications contain a first DNA sequence encoding a recombinant protein comprising a composite DNA binding domain of this invention (and may contain additional domains as discussed above) and a second DNA sequence containing a target gene linked to a DNA element to which the recombinant protein is capable of binding.
  • the second DNA sequence may contain a cloning site for insertion of a desired target gene by the practitioner.
  • the kit may further contain a third DNA sequence encoding a transcriptional activating domain and a second receptor domain, as discussed above.
  • kits may also contain a sample of a dimerizing agent capable of dimerizing the two recombinant proteins and activating transcription of the target gene.
  • plasmids are constructed in pET-19BHA, a pET-19B based vector modified such that all expressed proteins contain an amino-terminal Histidine "Tag” for purification and an epitope tag for immunoprecipitation.
  • pET-19B is a well-known vector for expression of heterologous proteins in E coli or in reticulocyte lysates.
  • pl9B2F Contains SREZBP zinc fingers 6 and 7 (amino acids 328 to 410) fused in frame to the epitope tag in pl9BHA.
  • DNA encoding ZBP zinc fingers 6 and 7 was generated by PCR using primers 2F-Xba5' and ZNF-Spe/Bam (see below). The resulting fragment was cut with Xbal and BamHI and ligated between the Xbal and BamHI sites of pET-19BHA.
  • pl9B4F Contains SREZBP zinc fingers 4, 5, 6 and 7 (amino acids 300 to 410) fused in frame to the epitope tag in pl9BHA.
  • a DNA fragment encoding ZBP zinc fingers 4, 5, 6 and 7 was generated by PCR using primers 4F-Xba5' and ZNF- Spe/Bam. The resulting fragment was cut with Xbal and BamHI and ligated between the Xbal and BamHI sites of pET-19BHA.
  • pl9B7F Contains SREZBP zinc fingers 1 to 7 (amino acids 216 to 410) fused in frame to the epitope tag in pl9BHA.
  • DNA encoding ZBP zinc fingers 1 to 7 was generated by PCR using primers 7F-Xba5' and ZNF-Spe/Bam. The resulting fragment was cut with Xbal and BamHI and ligated between the Xbal and BamHI sites of pET-19BHA.
  • pl9BFl Contains SREZBP zinc finger 1 (amino acids 204 to 241) fused in frame to the epitope tag in pl9BHA.
  • DNA encoding ZBP zinc finger 1 was generated by PCR using primers ZBPZF15' and ZBPZF13'. The resulting fragment was cut with Xbal and BamHI and ligated between the Xbal and BamHI sites of pET-19BHA.
  • ⁇ l9BF123 Contains SREZBP zinc fingers 1, 2 and 3 (amino acids 204 to 297) fused in frame to the epitope tag in pl9BHA.
  • DNA encoding ZBP zinc fingers 1, 2 and 3 was generated by PCR using primers ZBPZF15' and ZBPZF33'. The resulting fragment was cut with Xbal and BamHI and ligated between the Xbal and BamHI sites of pET-19BHA.
  • pl9BHH Contains the Phoxl homeodomain and flanking amino acids (amino acids 43 to 150 (Grueneberg et al. 1992. Science. 257: 1089-1095)) fused in frame to the epitope tag in pl9BHA.
  • DNA encoding the Phoxl fragment was generated by PCR using primers Phox HH5' Primer and Phox HH Spe/Bam. The resulting fragment was cut with Xbal and BamHI and ligated between the Xbal and BamHI sites of pET-19BHA.
  • pl9B2FHH Contains SREZBP zinc fingers 6 and 7 (amino acids 328 to 410) fused in frame to the epitope tag in pl9BHA followed by the Phoxl homeodomain (amino acids 43 to 150).
  • An Xbal-BamHI fragment from p!9BHH containing sequences encoding the Phoxl homeodomain was ligated between the Spel and BamHI sites of pl9B2F.
  • pl9B4FHH Contains SREZBP zinc fingers 4, 5, 6 and 7 (amino acids 300 to 410) fused in frame to the epitope tag in pl9BHA followed by the Phoxl homeodomain (amino acids 43 to 150).
  • An Xbal-BamHI fragment from pl9BHH containing sequences encoding the Phoxl homeodomain was ligated between the Spel and BamHI sites of pl9B4F.
  • pl9B7FHH Contains SREZBP zinc fingers 1 to 7 (amino acids 216 to 410) fused in frame to the epitope tag in pl9BHA followed by the Phoxl homeodomain (amino acids 43 to 150).
  • An Xbal-BamHI fragment from pl9BHH containing sequences encoding the Phoxl homeodomain was ligated between the Spel and BamHI sites of pl9B7F.
  • pl9BZFlHH Contains SREZBP zinc finger 1 (amino acids 204 to 241) fused in frame to the epitope tag in pl9BHA followed by the Phoxl homeodomain (amino acids 43 to 150). An Xbal-BamHI fragment from pl9BHH containing sequences encoding the Phoxl homeodomain was ligated between the Spel and BamHI sites of pl9BZFl.
  • pl9BZF123HH Contains SREZBP zinc finger 1, 2 and 3 (amino acids 204 to 297) fused in frame to the epitope tag in pl9BHA followed by the Phoxl homeodomain (amino acids 43 to 150).
  • An Xbal-BamHI fragment from pl9BHH containing sequences encoding the Phoxl homeodomain was ligated between the Spel and BamHI sites of pl9BZF123.
  • pl9BHH2F Contains Phoxl homeodomain (amino acids 43 to 150) fused in frame to the epitope tag in pl9BHA followed by ZBP zinc fingers 6 and 7 (amino acids 328 to 410). An Xbal-BamHI fragment from pl9B2F containing sequences encoding ZBP zinc fingers 6 and 7 was ligated between the Spel and BamHI sites of pl9BHH.
  • pl9BHH4F Contains Phoxl homeodomain (amino acids 43 to 150) fused in frame to the epitope tag in pl9BHA followed by ZBP zinc fingers 4, 5, 6 and 7 (amino acids 300 to 410). An Xbal-BamHI fragment from pl9B4F containing sequences encoding ZBP zinc fingers 4, 5, 6 and 7 was ligated between the Spel and BamHI sites of pl9BHH.
  • pl9BHH7F Contains Phoxl homeodomain (amino acids 43 to 150) fused in frame to the epitope tag in pl9BHA followed by ZBP zinc fingers 1 to 7 (amino acids 216 to 410). An Xbal-BamHI fragment from pl9B7F containing sequences encoding ZBP zinc fingers 1 to 7 was ligated between the Spel and BamHI sites of pl9BHH.
  • pl9BHHZFl Contains Phoxl homeodomain (amino acids 43 to 150) fused in frame to the epitope tag in pl9BHA followed by ZBP zinc finger 1 (amino acids 204 to 241). An Xbal-BamHI fragment from pl9BZFl containing sequences encoding ZBP zinc finger 1 was ligated between the Spel and BamHI sites of pl9BHH.
  • pl9BHHZF123 contains Phoxl homeodomain (amino acids 43 to 150) fused in frame to the epitope tag in pl9BHA followed by ZBP zinc fingers 1, 2 and 3
  • Zinc finger/Homeodomain hybrid proteins were expressed using the Promega TnT coupled reticulocyte lysate system. 4 Micrograms of each of the following constructs was added to a 50 microlitre translation mix: pl9B2FHH, pl9B4FHH, pl9B7FHH. pl9BHH was also included as a positive control.
  • Zinc Finger/Homeodomain hybrid proteins The DNA-binding specificity of Zinc Finger/Homeodomain hybrid proteins was determined as described (Pollock and Treisman, 1990, NAR. 18:6197-6204) except that 12CA5 antibody was used to immunoprecipitate protein-DNA complexes. Four cycles of selection were performed, and the resulting fragments were amplified and cloned into pUC119 for analysis.
  • 2F-Xba5' 5 • -TCAGTCTAGATGTAACATATGCCAGAAAGCCTTC-3 •
  • ZBPZF15' S'-TCAGTCTAGACATAAGAAAGTCCTCTCTAG-S 1
  • ZBPZF13' S -TCAGGGATCCTCTATATCAACTAGTAGGCTTCTCACCAAGATGG-S'
  • ZBPZF33' 5 , -TCAGGGATCCTCTATATCAACTAGTGGGCTCCTCCTGACTGTG-3 •

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne de nouvelles protéines chimères et des séquences d'ADN codant pour ces protéines, qui sont utiles pour la régulation de la transcription de gènes cibles dans des cellules ou des organismes modifiés par génie génétique les contenant. On décrit également des gènes de recombinaison cibles et d'autres systèmes utiles pour la mise en oeuvre de l'invention. Les gènes de recombinaison cibles comprennent une séquence d'ADN de recombinaison qui peut se lier au moins à deux domaines hétérologues pour la fixation à l'ADN, par exemple sous la forme d'une protéine composite ou d'un complexe de protéines se fixant à de l'ADN.
PCT/US1995/010557 1994-08-18 1995-08-18 Proteines composites se fixant a de l'adn et substances et procedes concernant ces proteines WO1996006110A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU33315/95A AU3331595A (en) 1994-08-18 1995-08-18 Composite dna-binding proteins and materials and methods relating thereto

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US29259994A 1994-08-18 1994-08-18
US8/292,599 1994-08-18
US37335195A 1995-01-17 1995-01-17
US8/373,351 1995-01-17
US48028995A 1995-06-07 1995-06-07
US8/480,289950607 1995-06-07

Publications (1)

Publication Number Publication Date
WO1996006110A1 true WO1996006110A1 (fr) 1996-02-29

Family

ID=27404139

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/010557 WO1996006110A1 (fr) 1994-08-18 1995-08-18 Proteines composites se fixant a de l'adn et substances et procedes concernant ces proteines

Country Status (2)

Country Link
AU (1) AU3331595A (fr)
WO (1) WO1996006110A1 (fr)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153383A (en) * 1997-12-09 2000-11-28 Verdine; Gregory L. Synthetic transcriptional modulators and uses thereof
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6479626B1 (en) 1998-03-02 2002-11-12 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US6503717B2 (en) 1999-12-06 2003-01-07 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US6733970B2 (en) 1998-11-09 2004-05-11 Gendaq Limited Screening system for zinc finger polypeptides for a desired binding ability
US6746838B1 (en) 1997-05-23 2004-06-08 Gendaq Limited Nucleic acid binding proteins
US6790941B2 (en) 1994-01-18 2004-09-14 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US6977154B1 (en) 1998-03-17 2005-12-20 Gendaq Limited Nucleic acid binding proteins
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7026462B2 (en) 2000-12-07 2006-04-11 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
USRE39229E1 (en) 1994-08-20 2006-08-08 Gendaq Limited Binding proteins for recognition of DNA
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US7273923B2 (en) 2001-01-22 2007-09-25 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
US7585849B2 (en) 1999-03-24 2009-09-08 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US7851216B2 (en) 2000-01-24 2010-12-14 Gendaq, Ltd. Methods and compositions for linking binding domains in nucleic acid binding proteins

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CELL, Volume 54, issued 15 July 1988, WEBSTER et al., "The Hormone-Binding Domains of the Estrogen and Glucocorticoid Receptors Contain an Inducible Transcription Activation Function", pages 199-207. *
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, Volume 49, Number 2/3, issued 1994, BERGMANN et al., "Bivalent Ligands as Probes of Estrogen Receptor Action", pages 139-152. *
MECHANISMS OF DEVELOPMENT, Volume 34, issued 1991, FORTINI et al., "The Drosophila Zhf-1 and Zhf-2 Genes Encode Novel Proteins Containing Both Zinc-Finger and Homeodomain Motifs", pages 113-122. *
MOLECULAR AND CELLULAR BIOLOGY, Volume 15, Number 3, issued March 1995, QI et al., "The Ligand-Binding Domains of the Thyroid Hormone/Retinoid Receptor Gene Subfamily Function In Vivo to Mediate Heterodimerization, Gene Silencing and Transactivation", pages 1817-1825. *
SCIENCE, Volume 251, issued 15 February 1991, WEINTRAUB et al., "The MyoD Gene Family: Nodal Point During Specification of the Muscle Cell Lineage", pages 761-766. *
SCIENCE, Volume 262, issued 12 November 1993, SPENCER et al., "Controlling Signal Transduction with Synthetic Ligands", pages 1019-1024. *
SCIENCE, Volume 267, issued 06 January 1995, POMERANTZ et al., "Structure-Based Design of Transcription Factors", pages 93-96. *

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790941B2 (en) 1994-01-18 2004-09-14 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
USRE42211E1 (en) 1994-08-20 2011-03-08 Gendaq, Limited Relating to binding proteins for recognition of DNA
USRE39229E1 (en) 1994-08-20 2006-08-08 Gendaq Limited Binding proteins for recognition of DNA
USRE45795E1 (en) 1994-08-20 2015-11-10 Gendaq, Ltd. Binding proteins for recognition of DNA
USRE45721E1 (en) 1994-08-20 2015-10-06 Gendaq, Ltd. Relating to binding proteins for recognition of DNA
USRE42150E1 (en) 1994-08-20 2011-02-15 Gendaq, Limited Binding proteins for recognition of DNA
US8617807B2 (en) 1997-05-23 2013-12-31 Gendaq Limited Nucleic acid binding proteins
US6866997B1 (en) 1997-05-23 2005-03-15 Gendaq Limited Nucleic acid binding proteins
US7700523B2 (en) 1997-05-23 2010-04-20 Gendaq Limited Nucleic acid binding polypeptide library
US7241574B2 (en) 1997-05-23 2007-07-10 Gendaq Ltd. Nucleic acid binding proteins
US6746838B1 (en) 1997-05-23 2004-06-08 Gendaq Limited Nucleic acid binding proteins
US7759059B2 (en) 1997-05-23 2010-07-20 Gendaq Limited, C/O Brobeck Hale And Dorr Nucleic acid binding proteins
US6153383A (en) * 1997-12-09 2000-11-28 Verdine; Gregory L. Synthetic transcriptional modulators and uses thereof
US6183965B1 (en) 1997-12-09 2001-02-06 President And Fellows Of Harvard College Synthetic transcriptional modulators and uses thereof
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
US6479626B1 (en) 1998-03-02 2002-11-12 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US7153949B2 (en) 1998-03-02 2006-12-26 Massachusetts Institute Of Technology Nucleic acid encoding poly-zinc finger proteins with improved linkers
US7928195B2 (en) 1998-03-02 2011-04-19 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US6903185B2 (en) 1998-03-02 2005-06-07 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US7595376B2 (en) 1998-03-02 2009-09-29 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US6977154B1 (en) 1998-03-17 2005-12-20 Gendaq Limited Nucleic acid binding proteins
US6733970B2 (en) 1998-11-09 2004-05-11 Gendaq Limited Screening system for zinc finger polypeptides for a desired binding ability
US6933113B2 (en) 1999-01-12 2005-08-23 Sangamo Biosciences, Inc. Modulation of endogenous gene expression in cells
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US6979539B2 (en) 1999-01-12 2005-12-27 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6824978B1 (en) 1999-01-12 2004-11-30 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7163824B2 (en) 1999-01-12 2007-01-16 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7177766B2 (en) 1999-01-12 2007-02-13 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US7220719B2 (en) 1999-01-12 2007-05-22 Sangamo Biosciences, Inc. Modulation of endogenous gene expression in cells
US6785613B2 (en) 1999-01-12 2004-08-31 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6607882B1 (en) 1999-01-12 2003-08-19 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7788044B2 (en) 1999-01-12 2010-08-31 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US8268618B2 (en) 1999-01-12 2012-09-18 Sangamo Biosciences, Inc. Repressing endogenous CCR5 gene expression in cells using engineered zinc finger proteins
US7985887B2 (en) 1999-01-12 2011-07-26 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US9491934B2 (en) 1999-01-12 2016-11-15 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US8383766B2 (en) 1999-03-24 2013-02-26 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US7585849B2 (en) 1999-03-24 2009-09-08 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US8524874B2 (en) 1999-03-24 2013-09-03 Sangamo Biosciences Position dependent recognition of GNN nucleotide triplets by zinc fingers
US7235354B2 (en) 1999-09-14 2007-06-26 Sangamo Biosciences, Inc. Functional genomics using zinc finger proteins
US6777185B2 (en) 1999-09-14 2004-08-17 Sangamo Biosciences, Inc. Functional genomics using zinc finger proteins
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US7943553B2 (en) 1999-12-06 2011-05-17 Sangamo Biosciences, Inc. Randomized libraries of zinc finger proteins
US7491531B2 (en) 1999-12-06 2009-02-17 Sangamo Biosciences, Inc. Randomized libraries of zinc finger proteins
US6503717B2 (en) 1999-12-06 2003-01-07 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US7851216B2 (en) 2000-01-24 2010-12-14 Gendaq, Ltd. Methods and compositions for linking binding domains in nucleic acid binding proteins
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US7026462B2 (en) 2000-12-07 2006-04-11 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US8071564B2 (en) 2000-12-07 2011-12-06 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7605140B2 (en) 2000-12-07 2009-10-20 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7560440B2 (en) 2000-12-07 2009-07-14 Sangamo Bioschiences, Inc. Regulation of angiogenesis with zinc finger proteins
US8680021B2 (en) 2001-01-22 2014-03-25 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US7273923B2 (en) 2001-01-22 2007-09-25 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US9234188B2 (en) 2001-01-22 2016-01-12 Sangamo Biosciences, Inc. Modified zinc finger binding proteins
US9234187B2 (en) 2001-01-22 2016-01-12 Sangamo Biosciences, Inc. Modified zinc finger binding proteins
US9238803B2 (en) 2001-01-22 2016-01-19 Sangamo Biosciences, Inc. Modified zinc finger binding proteins
US7705139B2 (en) 2001-01-22 2010-04-27 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US10344271B2 (en) 2001-01-22 2019-07-09 Sangamo Therapeutics, Inc. Modified zinc finger binding proteins
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US7939327B2 (en) 2002-08-29 2011-05-10 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes

Also Published As

Publication number Publication date
AU3331595A (en) 1996-03-14

Similar Documents

Publication Publication Date Title
WO1996006110A1 (fr) Proteines composites se fixant a de l'adn et substances et procedes concernant ces proteines
JP3817739B2 (ja) キメラｄｎａ結合性タンパク質
AU752129B2 (en) Chimeric transcriptional activators and compositions and uses related thereto
Kataoka et al. Small Maf proteins heterodimerize with Fos and may act as competitive repressors of the NF-E2 transcription factor
US6326166B1 (en) Chimeric DNA-binding proteins
US6117680A (en) Compositions and methods for regulation of transcription
US6015709A (en) Transcriptional activators, and compositions and uses related thereto
AU775988B2 (en) Ligand activated transcriptional regulator proteins
US6479653B1 (en) Compositions and method for regulation of transcription
AU2006312659B2 (en) Recombinant expression of multiprotein complexes using polygenes
de la Brousse et al. Molecular and genetic characterization of GABP beta.
US6306649B1 (en) Heterologous transcription factors
WO1997005249A9 (fr) Prolongement d'une surface d'interaction proteine-proteine afin d'inactiver le fonctionnement d'une proteine cellulaire
US20020048792A1 (en) Methods and materials for regulated production of proteins
Zhou et al. The yeast TATA-binding protein (TBP) core domain assembles with human TBP-associated factors into a functional TFIID complex
CA2375490A1 (fr) Facteurs de transcription oca-b chimeriques
JP2002529081A (ja) 生物学的事象のｆｋ５０６に基づく調節
CN118480526A (zh) 一种转座酶、转座子、转座子系统及其应用
WO2001098507A1 (fr) Facteurs de transcription hsf chimeres
Kaufmann et al. Target Site Determination for Xenopus Laevis Fork Head Related Transcription Factors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
WA Withdrawal of international application
NENP Non-entry into the national phase

Ref country code: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642